Bracco Imaging is highlighting new data on the use of gadobenate dimeglumine for breast MRI at a company-sponsored symposium at ECR 2014 in Vienna.
In 2011, a study, titled "Phase III Multicenter Double-Blind, Randomized, Crossover Study to Compare MultiHance With Magnevist in Contrast-enhanced Magnetic Resonance Imaging (MRI) of the Breast (DETECT trial)," compared the gadobenate dimeglumine contrast agent from Bracco with Magnevist, the gadopentetate dimeglumine contrast agent from Bayer HealthCare Pharmaceuticals. Bracco sponsored the study.
A new analysis of the data collected during the DETECT study, recently published in the Journal of Magnetic Resonance Imaging, also compared the diagnostic performance of MRI with conventional imaging techniques. The results showed highly significant superiority in malignant lesion detection rate for MRI enhanced with 0.1 mmol/kg gadobenate dimeglumine compared with mammography, ultrasound, and mammography and ultrasound combined.
The researchers reported lower false-positive detection rates with gadobenate dimeglumine-enhanced MRI than with both gadopentetate dimeglumine-enhanced MRI and conventional imaging techniques.
The new results support the value of MRI in detecting breast cancer, said Dr. Alberto Spinazzi, Bracco's head of global medical and regulatory affairs, adding that the findings also indicate that improved diagnostic performance on breast MRI may be achieved, if MRI contrast agents with high relaxivity are used.
In other company news, Bracco has also launched a new tailored protocol software package for multidetector-row CT (MDCT).
The software, available on Bracco's website, was developed by a group of radiologists and tailors contrast-enhanced MDCT scanning parameters to individual patients. It can be applied to a database of contrast-enhanced MDCT protocols that contains more than 500 combinations of CT scanners and CT applications for Bracco's tri-iodinated, nonionic contrast agent, Iomeron 400, as well as iopamidol in the 370 mg/mL concentration, the company said.
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)